Convergent Therapeutics
PrivateLast Round
Series A
Extension
Sep 24, 2024
Est. Valuation
$277.8M
Total Funding Raised
$130M
Company Overview
Convergent Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A Extension round in September 2024.
Convergent Therapeutics is a biotechnology company developing next-generation targeted radiopharmaceutical therapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Convergent Therapeutics Comparables
Compare Convergent Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Blue Earth Therapeutics Ltd | 93% | |
| ARTBIO | 93% | |
| Full-Life Technologies | 89% |
For institutional investors. Book with your work email.
Convergent Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 24, 2024 | ||||
| Series A | May 3, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Convergent Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| OrbiMed | Series A |
| Invus Opportunities | Series A |
| Novo Holdings | Series A Extension |
| Invus | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 2, 2026
Grew 26% QoQ, from 31 to 39 employees.
- Apr 30, 2026
Andrew Davis appointed Chief Business and Strategy Officer.
For institutional investors. Book with your work email.
Convergent Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Convergent Therapeutics's valuation, stock price, and market status.
Is Convergent Therapeutics a public or private company?
Convergent Therapeutics is a private company.
What is the current stock price of Convergent Therapeutics?
Convergent Therapeutics is a private company, so its shares have no public market price. Caplight tracks Convergent Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Convergent Therapeutics worth (valuation)?
Convergent Therapeutics's valuation is estimated at $277.8M based on funding round data.
Can I buy Convergent Therapeutics stock?
Convergent Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Convergent Therapeutics's last funding round?
Convergent Therapeutics's most recent funding round was Series A Extension on September 24, 2024.
Who are the main investors in Convergent Therapeutics?
Key investors in Convergent Therapeutics include RA Capital Management, OrbiMed, Novo Holdings.
Will Convergent Therapeutics IPO soon?
No public IPO plans have been announced for Convergent Therapeutics.
How can I track Convergent Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Convergent Therapeutics's shares on secondary markets.